pediatrix obstetrix medical group :: Article CreatorPediatrix Medical Group, Inc.
MEDNAX, Inc. Provides physician services including newborn, maternal-fetal, pediatric subspecialties, and anesthesia care. Its services include Neonatal Care, Maternal-Fetal Care, Anesthesia and Anesthesia Subspecialty Care, Pain Management and Other Pediatric Subspecialty Care. The company was founded by Roger J. Medel in 1979 and is headquartered in Sunrise, FL.
Pediatrix Medical Group, Inc. Company Stats
As of November 2024
Industry Health Care Equipment & Services Founded 1979 Headquarters Sunrise, Florida Country/Territory United States CEO James D. Swift Employees 8,070
SummaryAdditional DataAnalystsHistorical Quotes
Key Data
Day's Range
13.26 x 13.86
52 Week Range
6.62 x 17.67 Valuation Measures
Price to Sales (ttm)
0.56
Price to Book Value (ttm)
1.49
Price to Tangible Book Value (ttm)
N/A
Total Enterprise Value to EBIT (ttm)
7.80
Total Enterprise Value to EBITDA (ttm)
5.83
Total Enterprise Value to Total Revenue (ttm)
0.72 Profitability Metrics
Gross Margin (ttm)
22.57%
Operating Margin (ttm)
9.13%
Return on Assets (ttm)
5.25%
Return on Equity (ttm)
-12.28% Revenue and Earnings Metrics
Revenue Per Share (ttm)
24.16
Revenue Growth (y/o/y)
0.92%
EBITDA Growth (y/o/y)
11.28%
Diluted EPS Growth (y/o/y)
N/A Cash and Debt Metrics
Total Cash Per Share
2.73
All values as of most recently reported quarter unless otherwise noted.
Consensus Recommendation
Outperform
Range of Price Targets
17.00 to 21.00
Range of EPS
1.41 to 1.62
Range of Revenue
$1.8B to $1.96B
Consensus Price Target is the stock price analysts expect to see within a period of 0-18 months. EPS and Revenue estimates are for the next 12 months. DATE OPEN HIGH LOW CLOSE ADJUSTED CLOSE VOLUME Apr 4, 2025 13.58 13.86 13.26 13.51 13.51 823,937 Apr 3, 2025 14.19 14.39 13.92 14.14 14.14 549,956 Apr 2, 2025 14.27 14.85 14.27 14.81 14.81 501,596 Apr 1, 2025 14.44 14.68 14.21 14.51 14.51 485,994 Mar 31, 2025 13.95 14.66 13.91 14.49 14.49 857,693 Mar 28, 2025 14.91 15.02 14.06 14.16 14.16 670,821 Mar 27, 2025 14.81 15.20 14.67 15.02 15.02 595,558 Mar 26, 2025 14.80 14.99 14.65 14.74 14.74 489,767 Mar 25, 2025 14.58 14.87 14.51 14.63 14.63 618,849 Mar 24, 2025 14.42 14.73 14.24 14.54 14.54 594,109
Related People & Companies
1 hour ago
Musk Calls For United States And European Union To Move To Zero-Tariff System
President Donald Trump imposed tariffs of 20% on the European Union as part of his "Liberation Day" tariff policy.
2 hours ago
NCAA House Settlement Hearing Primer: Proposed Rule Changes
The NCAA's new rules proposed in the House settlement represent a tectonic shift in the college sports landscape.
2 hours ago
UFC Results: Josh Emmett Vs. Lerone Murphy Fight Card
Everything you need to know about tonight's UFC Vegas 105 card: Emmett vs. Murphy fight card. Results, video highlights, scorecards, and more for the UFC Fight Night.
2 hours ago
'The White Lotus' Season 3 Stars And Creator Tease 'Shocking' Finale
"The White Lotus" Season 3 creator Mike White and some of the show's stars are urging viewers to "get f—-ing ready" for a shocking season finale.
2 hours ago
'Yellowjackets' Season 3 Is Badly Mangling The Adult Storyline
Yellowjackets keeps letting everyone down in its third season, from the characters to the actors to the fans.
2 hours ago
Will There Be A '1923' Season 3? Here's The Disappointing News So Far
The "1923" Season 2 finale airs tonight on Paramount+. Will there be a Season 3, or is this the end of the "Yellowstone" prequel series? Here's what to know so far.
3 hours ago
'Sweet Sixteen' Competition Kicks Off Saturday For NCAA Gymnastics
The stage is set for college gymnastics' 'Sweet Sixteen.' This weekend, the nation's top programs compete to secure one of eight coveted spots at the 2025 NCAA Women's Gymnastics Championships.
3 hours ago
NCAA Coaching Carousel: Texas A&M Officially Hires Samford's Bucky McMillan
NCAA Coaching Carousel: Texas A&M Officially Hires Samford's Bucky McMillan
3 hours ago
The K-Drama 'Karma' Delivers But Not In A Way You Might Suspect
When Lee Hee-jun's character shows up at the hospital as a burn victim, he's treated by the doctor played by Shin Min-a, a woman he abused decades earlier.
4 hours ago
'Pulse': Why Does Danny In Netflix Medical Drama Look So Familiar?
"Pulse" — a new medical drama on Netflix — stars Willa Fitzgerald as Dr. Danny Simms. What else has Fitzgerald starred in?
4 hours ago
HBO Pays All 'The White Lotus' Stars The Same Amount, But Is That Really A Good Thing?
Equal pay sounds great on its face, but do we really want an industry where actors lose their ability to negotiate better contracts?
4 hours ago
Real Madrid Coach Ancelotti Makes Title Race Confession After Shock Valencia Loss
Real Madrid head coach Carlo Ancelotti admitted that winning La Liga is now more "complicated" after his team lost 2-1 to Valencia at the Bernabeu on Saturday.
5 hours ago
Anti-Trump 'Hands Off' Protests Planned In All 50 States Today: What To Know
More than 1,000 protests against President Donald Trump and Elon Musk are planned for Saturday in cities across all 50 states, with several international cities taking...
Nov 26, 2024
Meet America's Dream Employers 2025
Dream jobs really do come true. Forbes' inaugural list of dream employers feature companies that offer inspiring work, opportunities to grow, generous compensation and great benefits.
More Articles
Pediatrix Medical Stock Rallies 37.7% In 6 Months: More Room To Run?
Shares of Pediatrix Medical Group, Inc. MD have soared 37.7% in the past six months, outperforming the industry and sector's declines of 12.9% and 9.4%, respectively. The S&P 500 Index rose 4.6% in the same time frame. Favorable payer mix and positive patient volume trends should further lead to more price appreciation of this stock.
MD's Six-Month Price Performance
Zacks Investment Research
Image Source: Zacks Investment Research
Given the impressive performance so far, can investors still consider buying Pediatrix Medical stock, or should you book profits? Currently trading at $14.64, MD remains below its 52-week high of $17.67, suggesting potential for further growth. The stock is trading above its 50-day and 200-day moving averages, indicating solid upward momentum.
The rising share of commercial births in Florida is a crucial tailwind for the company. It is expected to support its margin growth. It is exiting its affiliated office-based practices, apart from maternal-fetal medicine, to focus on core hospital-based services. This is expected to contribute to its EBITDA improvement strategy.
Management continues to forecast adjusted EBITDA between $215 million and $235 million for 2025, the mid-point signaling a 0.4% improvement from the 2024 reported figure. Our model estimate for adjusted EBITDA is pegged at $219.8 million.
It also has an active inorganic growth profile aimed at expanding its national network of physician practices in women's and children's services. It acquired a maternal-fetal medicine practice in the first quarter of 2024 for $9.7 million.
Stable same-facility patient volume growth witnessed so far this year is likely to continue, supporting its top line. Moreover, its hospital contract administrative fees are on the rise, with a 4% increase in 2024.
Despite the recent growth in stock price, Pediatrix Medical is trading at a discount compared to the industry average. It presents a compelling investment opportunity with its attractive forward 12-month price-to-earnings ratio of 9.42, lower than the industry average of 15.72. The company has a Value Score of A.
The Zacks Consensus Estimate for 2025 adjusted earnings for Pediatrix Medical is currently pegged at $1.54 per share, indicating 2% year-over-year growth. The consensus mark for next year suggests a further 4.1% jump. It met earnings estimates in two of the past four quarters, met once and missed on the other occasion. This is depicted in the figure below.
Pediatrix Medical Group, Inc. Price and EPS Surprise
Pediatrix Medical Group, Inc. Price-eps-surprisePediatrix Medical Group, Inc. Quote
Story Continues
The Zacks Consensus Estimate for 2024 and 2025 revenues is pegged at $1.9 billion and $1.91 billion, respectively.
Pediatrix Medical has strong long-term potential with a growing focus on maternal-fetal medicine practice. Stable patient volume growth and streamlining initiatives bode well for the company. MD is well-poised for continued growth with rising commercial births in key markets, a completed transition to a hybrid RCM structure, and active M&A activity. All these factors make MD a compelling buy opportunity for investors.
Pediatrix Medical currently sports a Zacks Rank #1 (Strong Buy).
Investors can look at some other top-ranked stocks in the broader Medical space, like Doximity, Inc. DOCS, Universal Health Services, Inc. UHS and The Ensign Group, Inc. ENSG. While Doximity sports a Zacks Rank #1, Universal Health and Ensign carry a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for Doximity's 2025 bottom line suggests 37.9% year-over-year growth. DOCS witnessed 10 upward estimate revisions over the past 30 days against no movement in the opposite direction. It beat earnings estimates in each of the last four quarters, with the average surprise being 26%.
The Zacks Consensus Estimate for Universal Health's 2025 bottom line is pegged at $17.92 per share, which indicates 7.9% growth from a year ago. During the past 60 days, UHS witnessed four upward estimate revisions against one in the opposite direction. It beat earnings estimates in three of the last four quarters, missing once, with the average surprise being 15.5%.
The Zacks Consensus Estimate for Ensign's 2025 earnings implies a 13.5% improvement from the year-ago reported figure. ENSG beat earnings estimates in each of the last four quarters, with an average surprise of 1.5%. The consensus mark for its current-year revenues is pegged at $4.9 billion, which indicates a 14.3% year-over-year increase.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Universal Health Services, Inc. (UHS) : Free Stock Analysis Report
Pediatrix Medical Group, Inc. (MD) : Free Stock Analysis Report
The Ensign Group, Inc. (ENSG) : Free Stock Analysis Report
Doximity, Inc. (DOCS) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.Com).
Zacks Investment Research
Here's Why Pediatrix Medical Group (MD) Is A Strong Momentum Stock
It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors.
While you may have an investing style you rely on, finding great stocks is made easier with the Zacks Style Scores. These are complementary indicators that rate stocks based on value, growth, and/or momentum characteristics.
Different than value or growth investors, momentum-oriented investors live by the saying "the trend is your friend." This investing style is all about taking advantage of upward or downward trends in a stock's price or earnings outlook. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks.
Headquartered in Sunrise, FL, Pediatrix Medical Group, Inc. Changed its corporate name from Mednax, effective Jul 1, 2022, to improve brand awareness. It continues trading under its current ticker symbol, MD.
MD boasts a Momentum Style Score of B and VGM Score of A, and holds a Zacks Rank #1 (Strong Buy) rating. Shares of Pediatrix Medical Group has seen some interesting price action recently; the stock is down 0.8% over the past one week and up 0.5% over the past four weeks. And in the last one-year period, MD has gained 52.7%. As for the stock's trading volume, 708,231.63 shares on average were traded over the last 20 days.
A company's earnings performance is important for momentum investors as well. For fiscal 2025, five analysts revised their earnings estimate higher in the last 60 days for MD, while the Zacks Consensus Estimate has increased $0.08 to $1.55 per share. MD also boasts an average earnings surprise of 19.4%.
MD should be on investors' short list because of its impressive earnings fundamentals, a good Zacks Rank, and strong Momentum and VGM Style Scores.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Pediatrix Medical Group, Inc. (MD) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.Com).
Zacks Investment Research
Comments
Post a Comment